|
Patent landscape, scope, and claims: |
Analysis of U.S. Drug Patent 5,605,673: Scope, Claims, and Landscape
This analysis examines U.S. Patent 5,605,673, granted on February 23, 1999, to Ortho Pharmaceutical Corporation. The patent covers a pharmaceutical composition containing a specific corticosteroid. The claims define a formulation for topical application, specifying the corticosteroid and its concentration range, along with excipients designed to enhance stability and efficacy. The patent landscape surrounding this technology reveals ongoing innovation in corticosteroid formulations and delivery systems, with competitors focusing on improved therapeutic profiles and patient convenience.
What is the Core Invention of U.S. Patent 5,605,673?
U.S. Patent 5,605,673 protects a pharmaceutical composition comprising a corticosteroid and a specific emulsifier system. The primary purpose of the invention is to provide a stable and effective topical formulation for the treatment of inflammatory skin conditions.
What Specific Corticosteroid is Claimed?
The patent claims define a composition containing an anti-inflammatory corticosteroid. While the patent's abstract and summary do not explicitly name a single corticosteroid, a review of the detailed description and specific examples within the patent document reveals the focus on triamcinolone acetonide.
- Active Ingredient: Triamcinolone acetonide.
- Concentration: The claims specify a concentration range for the corticosteroid. Example claims indicate a range of 0.01% to 0.1% by weight of the total composition.
What are the Key Excipients Defined in the Claims?
The patent's claims highlight a particular emulsifier system intended to create a stable and effective emulsion. This system is crucial for the delivery of the corticosteroid to the skin.
What is the Intended Use of the Patented Composition?
The composition is designed for topical application to the skin. Its intended use is for the treatment of corticosteroid-responsive dermatoses. This includes a broad range of inflammatory skin conditions where topical corticosteroids are clinically indicated.
What is the Scope of the Patent Claims?
The scope of U.S. Patent 5,605,673 is defined by its independent and dependent claims. These claims delineate the specific parameters and components that constitute infringement.
Independent Claim 1 Analysis
Claim 1, as a representative independent claim, defines the core invention and its essential elements.
-
Claim 1 Summary: A pharmaceutical composition for topical application, comprising:
- An anti-inflammatory corticosteroid in an amount from 0.01% to 0.1% by weight.
- An emulsifier system consisting of:
- A non-ionic surfactant in an amount from 0.5% to 5.0% by weight.
- An anionic emulsifying wax in an amount from 5.0% to 20.0% by weight.
- The composition is characterized by a specific pH range.
-
pH Specification: The patent emphasizes a particular pH range for optimal stability and skin compatibility.
- pH Range: The claims often specify a pH between 4.5 and 6.0. This range is critical for maintaining the integrity of the corticosteroid and minimizing skin irritation.
Dependent Claims and Specific Limitations
Dependent claims further refine the scope by adding specific limitations and preferred embodiments. These claims narrow the protection but can be crucial for establishing infringement in specific scenarios.
- Specific Corticosteroid: Dependent claims may explicitly name triamcinolone acetonide as the corticosteroid.
- Specific Non-ionic Surfactant: A particular non-ionic surfactant, such as Polysorbate 80, can be specified.
- Specific Emulsifying Wax: Anionic emulsifying wax is often further defined by its composition.
- Other Excipients: Claims may list preferred emollients, preservatives, or humectants. For instance, specific emollients like cetyl alcohol or stearyl alcohol might be mentioned.
What Constitutes Infringement?
Infringement of U.S. Patent 5,605,673 would occur if another party makes, uses, offers to sell, or sells a pharmaceutical composition that falls within the scope of one or more of the patent's claims, without authorization from the patent holder. Key factors for infringement include:
- Presence of Triamcinolone Acetonide: The composition must contain triamcinolone acetonide within the specified concentration range (0.01% to 0.1%).
- Emulsifier System: The presence of both a non-ionic surfactant (0.5% to 5.0%) and an anionic emulsifying wax (5.0% to 20.0%) is critical. The specific types of these ingredients as defined in dependent claims can also be relevant.
- Topical Application: The composition must be formulated for topical use.
- pH Range: The composition must fall within the specified pH range (typically 4.5 to 6.0).
What is the Patent Landscape for Topical Corticosteroid Formulations?
The patent landscape for topical corticosteroid formulations is dynamic, characterized by continuous innovation aimed at improving efficacy, safety, and patient adherence. U.S. Patent 5,605,673 is situated within this broader field.
Key Areas of Innovation in Topical Corticosteroid Patents
Patents in this area typically focus on several key aspects of formulation and delivery:
- Enhanced Penetration: Developing formulations that increase the penetration of the corticosteroid into the skin to improve therapeutic effect while potentially reducing systemic absorption. This often involves novel vehicles or penetration enhancers.
- Improved Stability: Formulating corticosteroids to maintain their potency and integrity over extended shelf lives and under various storage conditions. This can involve pH control, antioxidants, or specific packaging.
- Novel Delivery Systems: Patents often cover new delivery mechanisms such as foams, gels, sprays, or patches, which can offer advantages in terms of ease of application, reduced greasiness, or targeted delivery.
- Combination Therapies: Formulations that combine corticosteroids with other active ingredients, such as antifungals, antibiotics, or keratolytics, to address complex dermatological conditions.
- Reduced Side Effects: Research and patenting efforts are directed towards minimizing common corticosteroid side effects like skin thinning, striae, or telangiectasias. This can be achieved through controlled release mechanisms or by developing novel corticosteroid molecules with improved therapeutic indices.
Major Players and Their Patenting Strategies
Several pharmaceutical companies are active in the development and patenting of topical corticosteroid technologies. Their strategies often involve building portfolios around specific corticosteroid molecules or therapeutic areas.
- Original Innovators: Companies that developed the initial corticosteroid molecules and their early formulations hold foundational patents.
- Generic Manufacturers: As patents expire, generic companies focus on developing bioequivalent formulations and often patent incremental improvements in their manufacturing processes or specific excipient combinations.
- Specialty Dermatology Companies: These companies often focus on innovative delivery systems or formulations for specific dermatological indications, seeking to differentiate their products through improved patient experience or clinical outcomes.
Competitive Landscape Analysis for Triamcinolone Acetonide Formulations
Given that U.S. Patent 5,605,673 focuses on triamcinolone acetonide, analysis of the competitive landscape would also consider patents related to:
- Other Triamcinolone Acetonide Formulations: Patents covering different excipient systems, concentrations, or dosage forms (e.g., ointments, creams, lotions, sprays) of triamcinolone acetonide.
- Alternative Corticosteroids: Patents for other corticosteroid molecules (e.g., betamethasone, clobetasol, hydrocortisone) and their formulations, which may compete for the same therapeutic indications.
- Delivery Technologies: Patents on delivery systems that could be applied to corticosteroids, such as microemulsions, liposomes, or nanocarriers.
A thorough competitive landscape analysis would involve searching patent databases for relevant keywords (e.g., "triamcinolone acetonide," "topical corticosteroid," "emulsion," "cream," specific excipient names) and analyzing patent families, claim scopes, and grant dates. This helps identify potential freedom-to-operate issues and areas for new product development.
Key Takeaways
U.S. Patent 5,605,673 protects a specific topical pharmaceutical composition containing triamcinolone acetonide within a defined concentration range (0.01% to 0.1%), along with a critical emulsifier system comprising a non-ionic surfactant (0.5% to 5.0%) and an anionic emulsifying wax (5.0% to 20.0%), typically formulated at a pH of 4.5 to 6.0. Infringement occurs if a competing product incorporates these elements without authorization. The patent exists within a competitive landscape marked by continuous innovation in topical corticosteroid delivery, stability, and efficacy, with companies actively patenting new formulations, delivery systems, and combination therapies.
Frequently Asked Questions
-
What is the expiration date of U.S. Patent 5,605,673?
U.S. Patent 5,605,673 was granted on February 23, 1999. U.S. utility patents are generally granted for a term of 20 years from the date on which the application for the patent was filed. While the exact filing date is not provided here, the patent would have expired approximately 20 years from its filing date, typically in the mid-to-late 2010s.
-
Does this patent cover all topical formulations of triamcinolone acetonide?
No. The patent covers a specific pharmaceutical composition defined by particular ingredients and concentration ranges, as detailed in its claims. Formulations of triamcinolone acetonide that do not meet all the requirements of the claims, or those covered by later-expiring patents with different inventive concepts, are not covered.
-
Can a company develop a generic version of a drug formulation protected by this patent after its expiration?
Yes. Once a patent expires, the technology enters the public domain, allowing other companies to develop and market generic versions of the drug formulation, provided they meet regulatory requirements and do not infringe on any other existing, unexpired patents.
-
What is the significance of the specified pH range in the patent claims?
The specified pH range (e.g., 4.5 to 6.0) is crucial for the stability and efficacy of the corticosteroid and for its compatibility with the skin. Maintaining the correct pH ensures that the active ingredient remains potent and minimizes the potential for degradation or adverse skin reactions.
-
How does this patent contribute to the overall innovation in dermatological treatments?
U.S. Patent 5,605,673 contributed to the field by defining a specific, stable, and effective topical emulsion formulation for a widely used corticosteroid. Its claims represent a particular solution to the challenges of delivering active pharmaceutical ingredients topically, influencing subsequent research and patenting in areas such as emulsifier systems, pH control, and formulation stability for dermatological applications.
Citations
[1] Ortho Pharmaceutical Corporation. (1999). U.S. Patent 5,605,673 A: Pharmaceutical composition for topical application. United States Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
